Investors Purchase High Volume of Call Options on Bristol Myers Squibb (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) saw some unusual options trading activity on Thursday. Investors acquired 34,923 call options on the company. This represents an increase of approximately 49% compared to the average volume of 23,471 call options.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA accepted Bristol Myers Squibb’s NDA for mezigdomide in combination treatment for relapsed or refractory multiple myeloma, a meaningful regulatory step that could expand BMY’s oncology growth prospects if approved. Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
• Positive Sentiment: Unusual options trading showed elevated call buying, suggesting some traders are positioning for more upside in BMY shares near term.
• Positive Sentiment: Zacks highlighted Bristol Myers Squibb as a strong value stock and noted the company’s attractive valuation characteristics, which may be supporting investor interest. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Recent articles also note that BMY is drawing investor attention and may have a decent chance of another earnings beat, but these comments are mostly screening-based and do not appear to be tied to a new fundamental catalyst. Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Analysts at Wells Fargo reportedly initiated or maintained a Hold view, which does not add a strong directional signal for the stock. Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo
• Negative Sentiment: Earlier market commentary said BMY underperformed peers, suggesting the shares have faced some relative pressure even as fresh pipeline news emerges. Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors

Analyst Ratings Changes

Several research analysts have weighed in on BMY shares. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Bank of America reduced their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Weiss Ratings restated a “hold (c+)” rating on shares of Bristol Myers Squibb in a report on Thursday, July 2nd. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $61.25.

Bristol Myers Squibb Price Performance

Shares of BMY stock traded up $1.45 during trading hours on Thursday, hitting $60.17. The company had a trading volume of 4,729,511 shares, compared to its average volume of 12,316,050. The firm has a market capitalization of $122.86 billion, a price-to-earnings ratio of 16.89, a PEG ratio of 0.16 and a beta of 0.23. The firm’s fifty day moving average is $56.84 and its 200 day moving average is $57.72. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts predict that Bristol Myers Squibb will post 6.33 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds have recently modified their holdings of BMY. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Bayban acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the fourth quarter worth $32,000. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.